Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Insud’s Oral Contraceptive Filed in South Korea: ASKA
ASKA Pharmaceutical said on April 7 that drospirenone, an oral contraceptive in-licensed from Spain-based Insud Pharma, has been filed in South Korea via local sublicensee Hyundai Pharm. The Japanese company had acquired the development and marketing rights for the drug…
To read the full story
Related Article
- Insud/ASKA’s Birth Control Pill Approved in South Korea
August 19, 2024
- ASKA Licenses Korean Rights for Birth Control Pill Drospirenone
June 21, 2022
- ASKA Bags Japan Rights for Cervical Dysplasia Therapy from Kyoto Univ. Spinoff
January 16, 2020
- ASKA Grabs Japan, South Korea Rights to Insud’s Oral Contraceptive
January 9, 2020
BUSINESS
- Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
- Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
- Expert Welcomes Talvey-Tecvayli Combo for Difficult-to-Treat MM
July 10, 2026
- Axcelead Teams Up with Mitsubishi to Expand Drug Discovery Support Biz
July 10, 2026
- Roche PD-L1 Test Approved for Imfinzi in Endometrial Cancer
July 10, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…